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ABSTRACT
Transcription of hepatitis B virus (HBV) from the co-
valently closed circular DNA (cccDNA) template is
essential for its replication. Suppressing the level
and transcriptional activity of cccDNA might have
anti-HBV effect. Although cellular transcription fac-
tors, such as CREB, which mediate HBV transcrip-
tion, have been well described, transcriptional coac-
tivators that facilitate this process are incompletely
understood. In this study we showed that CREB-
regulated transcriptional coactivator 1 (CRTC1) is
required for HBV transcription and replication. The
steady-state levels of CRTC1 protein were elevated
in HBV-positive hepatoma cells and liver tissues. Ec-
topic expression of CRTC1 or its homolog CRTC2
or CRTC3 in hepatoma cells stimulated the activ-
ity of the preS2/S promoter of HBV, whereas over-
expression of a dominant inactive form of CRTC1
inhibited HBV transcription. CRTC1 interacts with
CREB and they are mutually required for the recruit-
ment to the preS2/S promoter on cccDNA and for
the activation of HBV transcription. Accumulation
of pregenomic RNA (pgRNA) and cccDNA was ob-
served when CRTC1 or its homologs were overex-
pressed, whereas the levels of pgRNA, cccDNA and
secreted HBsAg were diminished when CRTC1 was
compromised. In addition, HBV transactivator pro-
tein HBx stabilized CRTC1 and promoted its activity
on HBV transcription. Our work reveals an essential
role of CRTC1 coactivator in facilitating and support-
ing HBV transcription and replication.
INTRODUCTION
Hepatitis B virus (HBV), a member in the family ofHepad-
naviridae, has a DNA genome 3.2 kb in size which is par-
tially double stranded. Over 350 million people are chroni-
cally infected with HBV worldwide, including ∼10% of the
population inHongKong andChina, 15–40% of whomwill
terminally develop severe liver diseases including hepatocel-
lular carcinoma (HCC) (1). Although multiple factors are
involved in the development of HCC in HBV carriers, high
level of HBV DNA has been identified as a major risk (2).
HBV infects hepatocytes that express its receptor named
sodium taurocholate cotransporting polypeptide (3). Upon
viral entry and release of genetic material, covalently closed
circular DNA (cccDNA) is generated from relaxed circu-
lar DNA (rcDNA) and complexed with different viral pro-
teins, histones, transcription factors and coactivators to
form a nuclear minichromosome, which serves as a central
template for all HBV transcription (4,5). Transcription of
pregenomic RNA (pgRNA) from cccDNA is rate-limiting
in genome amplification and replication. cccDNA can be
amplified through an unknown mechanism (6). The stabil-
ity of the cccDNApool is amajor determinant in viral clear-
ance. cccDNA is refractory to antivirals such as nucleoside
or nucleotide analogs. cccDNA is also accounted for viral
relapse after cessation of anti-HBV therapy (5). cccDNA is
therefore an important target for better control and elimina-
tion of HBV infection (7,8). In line with this, understanding
the mechanism by which HBV transcription from cccDNA
is regulated might reveal new strategies for therapeutic in-
tervention.
HBV transcription is mediated by transcription factors
recruited to cccDNA including CREB, ATF1, STAT1 and
KLF15 (4,9). CREB is essential for HBV replication and it
binds to the cAMP response elements (CREs) located at the
X and preS2 promoters of the viral genome (10,11). Tran-
scriptional coactivators such as p300, pCAF and CREB
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binding protein (CBP) are also known to be recruited to
cccDNA to support HBV transcription through acetyla-
tion of histones and transcription factors (12). In addition,
CREB-regulated transcriptional coactivator 2 (CRTC2) is
also thought to potentiate HBV transcription through the
induction of PGC1 (13). However, the roles of additional
CRTC transcriptional coactivators in relation to the func-
tion of CREB in HBV transcription have not been charac-
terized.
CRTCs are potent coactivators of CREB-dependent
transcription from both canonical cellular CREs and the
non-canonical viral CREs found in the long terminal re-
peats of the oncogenic retrovirus human T-cell leukemia
virus type 1 (14,15). There are three isoforms of human
CRTCs, namely CRTC1, CRTC2 and CRTC3. They inter-
act with CREB and cooperate with p300/CBP to potentiate
CREB-dependent transcription (15). Because various sig-
nals converge on CRTCs to exert their effects on the tran-
scription of CREB-regulated genes, they are the targets of
pharmaceutical agents such as metformin, a widely pre-
scribed drug for type II diabetes (16). Thus, full character-
ization of the roles of CRTCs in HBV transcription might
reveal new targets for therapeutic intervention.
HBV encodes a multifunctional viral oncoprotein HBx.
It acts as a transcriptional activator that modestly acti-
vates cellular transcription factors including CREB, NF-
B and AP1 (17). HBx is required for HBV transcription
and productive infection in vivo (18,19). HBx does not bind
DNA. Its ability to activate HBV promoters is mediated
through CREB (10,20). Mechanistically, HBx enhances
CREB dimerization and potentiates coactivator function
of p300/CBP (20,21). However, the interplay among HBx,
CREB and CRTCs in HBV transcription remains to be un-
derstood. Particularly, it will be of interest to see whether
and how HBx interacts with and modulates CRTC activity.
In this study, we documented the requirement of CRTC1
in HBV transcription. CRTC1 protein was more abun-
dantly detected in liver tissues of HBV-infected individuals.
The HBV-induced stabilization of CRTC1 protein was fur-
ther validated. We provided the first evidence that CRTC1
and its homologs CRTC2 and CRTC3 cooperate with HBx
to activate HBV transcription through CREB. Our work
suggests a new model in which HBV, through mutual stabi-
lization ofHBx andCRTC1, usurps CRTC1 transcriptional
coactivator to augment CREB-mediated activation of HBV
transcription.
MATERIALS AND METHODS
Human liver tissue samples
Sampling of human liver tissues was performed as previ-
ously described (22). Seven Chinese patients who had surgi-
cal resection of liver at QueenMaryHospital ofHongKong
were randomly selected for study. All specimens were ob-
tained immediately after surgical resection, snap-frozen in
liquid nitrogen and stored at −70◦C. Frozen sections were
cut from non-tumorous liver and histological examination
was performed to verify homogeneous cell populations of
tissues.Hepatitis B surface antigen (HBsAg)was detected in
the sera of patients 127, 128, 216 and 229, but not patients
210, 213 and 223. HBV DNA status in liver samples was
also verified. The use of human liver tissues was approved
by the Joint Institutional Review Board of the University
of Hong Kong and Hospital Authority Hong Kong West
Cluster.
Cell culture and transfection
HepG2.2.15 cells were cultured in Dulbecco’s Modified Ea-
gle Medium supplemented with 10% fetal calf serum, 2
mM L-glutamine and 380 g/ml G418. Plasmid DNA was
transfected into HepG2 cells using GeneJuice transfection
reagent (Novagen). siRNAwas transfected intoHepG2 and
HepG2.2.15 cells using Lipofectamine 2000 (Invitrogen).
Plasmids
Reporter plasmids preS2-Luc, X-Luc, preS1-Luc and C-
Luc were derived from pGL3-Basic (Promega). preS1 (nu-
cleotides 2710–2834), preS2 (nucleotides 2966–152), X (nu-
cleotides 950–1310) and C (nucleotides 1403–1817) pro-
moter sequences were amplified by polymerase chain reac-
tion (PCR) from the HBV genome of adw2 subtype (Gen-
bank AM282986) in plasmid pHBV1.3D, which has been
described elsewhere (9,23). Expression plasmids for CREB,
A-CREB, CRTC1, CRTC2, CRTC3, CRTC1-S167A and
CRTC1-M1, as well as reporter plasmid pCRE-Luc have
also been detailed previously (15,24). The expression plas-
mid for HBx was based on the pCAGEN vector and the
HBx open reading frame (nucleotides 1374–1838) was PCR
amplified from pHBV1.3D with the addition of a Flag-HA
tag to its 5′ end. The X-deficient pHBV1.3D was made
by converting the eighth codon of HBx to a stop codon.
Themutagenic primers were 5′-CGCGAAGGATCCAGT-
TAGCAGTACAACCTAGCA-3′ and 5′-GCGCTTCCTA
GGTCAATCGT CATGTTGGAT CGT-3′. A similar con-
struct has been described elsewhere (25). Expression vector
for the lysine-free (K0) mutant of ubiquitin is a kind gift
from Dr James Chen (26).
Luciferase reporter assays
Dual luciferase assay was performed as described previ-
ously (27,28). Transfection efficiencies were normalized to
a control plasmid expressing Renilla luciferase (pSV-RLuc
from Promega).
Coimmunoprecipitation and chromatin immunoprecipitation
Coimmunoprecipitation (Co-IP) and chromatin immuno-
precipitation (ChIP) assays were performed as previously
described (22,29). For Co-IP, HepG2 or HepG2.2.15 cells
grown in a 100-mm petri dish were harvested into 1
ml of immunoprecipitation buffer (50 mM Tris-HCl, pH
7.5, 100 mM NaCl, 0.5 mM EDTA, 1% NP-40, 0.1%
sodium dodecyl sulfate, 1% sodium deoxycholate, 1 mM
dithiothreitol, 20 mM -glycerophosphate, 1 mM sodium
vanadate and 1 mM phenylmethylsulfonyl fluoride). Flag-
HBx, CRTC1-V5 and endogenous CREB proteins were
immunoprecipitated from the cleared lysate by incuba-
tion at 4◦C for 2 h. For ChIP, HepG2 cells were cross-
linked with 1% formaldehyde for 10 min at room tem-
perature. Cells were washed and then lysed in the pres-
ence of protease inhibitor cocktail. The DNA–protein
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complex was immunoprecipitated. The cross-link was re-
versed by proteinase K. The DNA was purified by phenol-
chloroform extraction. Promoter sequence spanning the
two CRE enhancers in the preS2 promoter was analyzed
by quantitative PCR using primers 5′-CCCTGCTCCG
AATATTGCCT C-3′ and 5′-ACACACGGGT GATCCC-
CCTAG-3′. For cccDNAChIP, quantitative PCR was per-
formed with primers 5′-CTCCCCGTCT GTGCCTTCT-3′
and 5′-GCCCCAAAGC CACCCAAG-3′ that selectively
amplify cccDNA as previously described (7,12,29).
RNA interference
HepG2 and HepG2.2.15 cells were transfected with 100
nMof siRNAusing Lipofectamine 2000 (Invitrogen). RNA
interference (RNAi) experiments were performed as de-
scribed (27,30). siRNAs were listed in Supplementary Table
S1.
Real-time RT-PCR
Real-time reverse transcription-PCR (RT-PCR) was per-
formed as described (27,30). Normalization was made
to glycerialdehyde-3-phosphate dehydrogenase (GAPDH)
mRNA. Quantitation of target mRNA was achieved with
the comparative Ctmethod. Relative expression level of tar-
get mRNA was calculated from 2−Ct. Primers were listed
in Supplementary Table S1.
RESULTS
CRTC1 protein was abundantly detected in HBV-infected
cells
To identify proteins that are specifically expressed in HBV-
infected liver, we performed a pilot proteomic profiling
study using human liver tissues that are infected with HBV.
We noted that CRTC1, but not CRTC2 or CRTC3, was
more abundantly detected in infected versus uninfected
samples (data not shown). We previously showed the re-
quirement of CRTC coactivators in transcriptional activa-
tion of human T-cell leukemia virus type 1 (15). We there-
fore sought to investigate the expression and function of
CRTC1 in HBV-infected cells.
To model HBV genome replication, we used HepG2
cells transfected with pHBV1.3D, an HBV molecular clone
(9,23). In addition, HepG2.2.15 cells, which constitutively
produce HBV (31), were also employed. Expression of
endogenous CRTC1 protein was more pronounced in
pHBV1.3D-transfected HepG2 and in HepG2.2.15 cells
(Figure 1A and B, lanes 2 and 3 or 2–4 compared to
1), whereas the steady-state levels of CREB, CRTC2 and
CRTC3 remained largely unchanged. In contrast, the
mRNA levels of all three CRTCs were comparable in the
presence and absence of HBV (Figure 1C), indicating that
the effect on CRTC1 occurs at protein but not mRNA level.
To verify CRTC1 expression in natural infection ofHBV,we
examined a small number ofHBV-positive orHBV-negative
human liver tissues. CRTC1 protein expression was 6- to
18-fold more abundant in HBV-positive samples than in
HBV-negative ones (Figure 1D). One plausible interpreta-
tion to these data is that CRTC1 protein is stabilized in
HBV-infected cells.
Overexpression of CRTCs promoted HBV transcription and
replication
Given that CRTC1 protein is abundant in HBV-infected
cells, it will be of interest to assess the influence of
CRTC coactivators on HBV transcription. CRTCs poten-
tiate CREB-dependent transcription depending on the pro-
moter context (32,33). Although CRE elements are found
in preS2 and X promoters of HBV (10,11), it remains to be
determined whether they are activated by CRTCs.With this
in mind, we asked how CRTCs might affect transcriptional
activity of these two promoters. All three CRTCs were ex-
pressed to comparable levels in HepG2 cells (Figure 2A).
Whereas all three CRTCs activated preS2 promoter signifi-
cantly (Figure 2B, groups 2–4 compared to 1), they hadmin-
imal or no influence on basal activity of X promoter in the
same setting (Figure 2C). Hence, CRTCs are capable of ac-
tivating HBV transcription from the preS2 promoter.
CRTC2 has recently been shown to promote HBV tran-
scription and replication through the induction of a CREB-
regulated gene, PGC1, which in turn activates the core
promoter of HBV modestly (13). Consistent with this, we
observed moderate activation of the preS1 and core pro-
moter by all three CRTCs (Supplementary Figure S1A and
B, groups 2–4 compared to 1). Because CRTCs activate
CRE and preS2 promoter much more potently (Figure 2A
and Supplementary Figure S1C) and no CRE was found in
preS1 or core promoter, our further analysis will be focused
on the preS2 promoter only.
To verify the coactivator function of CRTCs on the preS2
promoter, we performed ChIP assay to assess its recruit-
ment to the CRE elements in this promoter. Indeed, all
three CRTCs were recruited to preS2-CRE in pHBV1.3D-
transfected HepG2 cells (Figure 2D, groups 3–5 compared
to 2). Since CRTCs are thought to work in concert with
CREB, we further examined the recruitment of endogenous
CREB to preS2-CRE. We found that the HBV-induced re-
cruitment of CREB to preS2-CRE was more pronounced
when CRTC1/2/3 was overexpressed (Figure 2E, groups 3–
5 compared to 2), indicating that CRTCs and CREB might
activate transcription from the preS2 promoter coopera-
tively. In line with this, all three CRTCs were also recruited
to cccDNA (Figure 2F, groups 3–5 compared to 2). Col-
lectively, our results supported the model in which CRTCs
facilitate HBV transcription by enhancing the recruitment
of CREB to the preS2 promoter.
Activation of HBV transcription might accelerate other
steps in viral replication. To verify this, wemeasured the lev-
els ofHBVpgRNAand cccDNA in pHBV1.3D-transfected
HepG2 cells. Upon pHBV1.3D transfection, basal expres-
sion of pgRNA as well as nuclear and cell-free cccDNA
was detected (Figure 3A and B, group 2, and Figure 3C,
lane 3). Intriguingly, their expression was boosted when
CRTC1/2/3 was overexpressed (Figure 3A and B, groups
3–5 compared to 2 and Figure 3C, lanes 4–6 compared to
3). In other words, overexpression of CRTCs not only stim-
ulates HBV transcription, but also promotes its replication.
To determine the requirement of CREB in CRTC-
induced activation of HBV replication, we employed A-
CREB, a previously described dominant inactive form
of CREB (34). The expression of A-CREB abrogated
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Figure 1. Detection of CRTC1 protein in HBV-positive cells. (A) Detection of CRTC1 protein in pHBV1.3D-transfected HepG2 cells. Cells were seeded
into a six-well plate and transfectedwith escalating amount of pHBV1.3D (1 or 2g). Cells were harvested 48 h after transfection. Cell lysates were analyzed
by western blotting with rabbit anti-CRTC1 (Cell Signaling), rabbit anti-CREB (Cell Signaling) and mouse anti--actin (Sigma) antibodies. (B) Detection
of CRTC proteins in HepG2.2.15 cells. Western blotting was performed with rabbit anti-CRTC1/2/3 (Cell Signaling), mouse anti-HBx (Millipore) and
anti--tubulin (Sigma); -tub: -tubulin. (C) Quantitative RT-PCR analysis of CRTC mRNA. HepG2 cells were transfected with empty vector (vec) or
pHBV1.3D (2 g). The difference between bars 1 and 4 is statistically not significant (n.s.) by Student’s t test (P = 0.98). (D) Detection of CRTC1 protein
in human liver samples. Band intensity was measured by densitometry.
CRTC1-induced augmentation of cccDNA formation in
pHBV1.3D-transfected HepG2 cells (Figure 3D, group 4
compared to 2 and 3). Consistent with this, the increase
in cccDNA level in the presence of CRTC1 in HepG2.2.15
cells was blunted when A-CREBwas overexpressed (Figure
3E, group 3 compared to 1 and 2). Thus, CREB is required
for CRTC1-induced activation of HBV replication.
Depletion of CRTC1 inhibited HBV replication
Complementary to the gain-of-function analyses described
above, loss-of-function experiments were also performed to
establish the physiological importance of CRTC1 in HBV
transcription and replication. Because only CRTC1 levels
were elevated in HBV-infected cells (Figure 1), we chose to
focus on CRTC1 in the loss-of-function study. We first uti-
lized M1-CRTC1, a truncated and dominant inactive mu-
tant of CRTC1, which we constructed and successfully used
previously (24,27,30).When the dose ofM1-CRTC1was es-
calated in HepG2 cells, the activity of the preS2 promoter
was diminished progressively (Figure 4A, groups 2–4 com-
pared to 1). Moreover, the intracellular cccDNA pool de-
creased inM1-CRTC1-expressing HepG2 cells (Figure 4B).
Accordingly, the pgRNA levels also declined in a dose-
dependent manner in these cells (Figure 4C, groups 3 and 4
compared to 2).
We next employed RNAi to silence endogenous CRTC1
expression in HepG2 cells. Two independent siRNAs di-
rected against CRTC1 (siCRTC1-a and siCRTC1-b) effi-
ciently depleted its protein expression (Figure 4D, lanes
2 and 3 compared to 1 in the blot). The silencing effect
was highly specific since only CRTC1 mRNA was affected,
whereas the levels of CRTC2 transcript remained unaltered
(Figure 4D, groups 3 and 5 compared to 1, and groups 4 and
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Figure 2. Overexpression of CRTC coactivators augmented HBV transcription. (A) Overexpression of CRTC1/2/3 in HepG2 cells. Western blotting was
performed with mouse anti-V5 (Invitrogen). (B) Effect on preS2 promoter activity. HepG2 cells were transfected with preS2-Luc (100 ng) and pcDNA3.1-
V5/His-CRTC1/2/3 (100 ng). Dual luciferase assay was performed. Results represent means from three independent experiments and error bars indicate
SD. The difference between groups 1 and 3 is statistically significant by Student’s t test (P = 0.000024, highlighted with ***). (C) Effect on X promoter
activity. The difference between groups 1 and 2 is statistically not significant (n.s.) by Student’s t test (P = 0.49). (D) CRTC recruitment to CREs in the
preS2 promoter. HepG2 cells were transfected with the indicated plasmids. ChIP was performed to precipitate V5-CRTC1/2/3-preS2 promoter complex
using mouse anti-V5 (Invitrogen) and the CRE sequence in the preS2 promoter was analyzed by quantitative PCR. Results represent relative recruitment
measured in arbitrary units (AU). The difference between groups 2 and 5 is statistically significant by Student’s t test (P= 0.0032, highlighted with **); N.D.:
not detected. (E) Impact of CRTC coactivators on CREB recruitment to the preS2 promoter. ChIP was performed to precipitate CREB-preS2 promoter
complex using rabbit anti-CREB (Cell Signaling). The difference between groups 2 and 5 is statistically significant by Student’s t test (P= 0.029, highlighted
with *). (F) CRTC recruitment to cccDNA. ChIP was performed to obtain V5-CRTC1/2/3-DNA complex using mouse anti-V5 and the cccDNA-specific
sequence was analyzed by quantitative PCR. The difference between groups 2 and 3 is statistically significant by Student’s t test (P = 0.031, highlighted
with *).
6 compared to 2 in the bar chart). In keeping with this, the
recruitment of endogenous CREB to preS2-CRE was pre-
vented in CRTC1-depleted cells (Figure 4E, groups 3 and
4 compared to 2), indicating the physiological importance
of CRTC1 in mobilizing CREB to the preS2 promoter to
activate transcription. Furthermore, the levels of pgRNA,
nuclear cccDNA and secreted HBsAg were declined when
CRTC1 was compromised (Figure 4F–H, groups 3 and
4 compared to 2). Collectively, our results suggest that
CRTC1 is required for HBV transcription and replication.
CREB is required for CRTC activation of HBV transcription
The importance of CREB in HBV transcription prompted
us to investigate whether CRTC1 activation of the preS2
promoter requires CREB function. As a first step, we gen-
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Figure 3. Overexpression of CRTC coactivators promoted HBV replication. (A) CRTC coactivators augmented pgRNA expression. HepG2 cells were co-
transfected with pcDNA3.1-V5/His-CRTC1/2/3 and pHBV1.3D. Cells were harvested 48 h post-transfection. Total RNA was extracted and cDNA was
synthesized. Quantitative RT-PCR was performed to analyze the relative levels of pgRNA. The difference between bars 2 and 3 is statistically significant
by Student’s t test (P = 0.0016, highlighted with **); N.D.: not detected. (B) CRTC coactivators promoted cccDNA formation. Nuclear fraction was
extracted. DNAwas isolated and treated with plasmid-safe DNase I (Epicentre). Treated fraction was analyzed for cccDNAby quantitative PCR.GAPDH
transcript was amplified from untreated fraction for normalization. The difference between groups 2 and 3 is statistically significant by Student’s t test
(P = 0.00029, highlighted with ***). (C) CRTC coactivators increased cccDNA production in cell-free medium. HepG2 cells were co-transfected with
pcDNA3.1-V5/His-CRTC1/2/3 and pHBV1.3D for 48 h. Culture medium was harvested and centrifugated to remove debris. Cleared medium was boiled
for 15 min, centrifugated at 13 500 rpm for 15 min. Supernatant was collected, treated with plasmid-safe DNase I (Epicentre) and analyzed for cccDNA
(highlighted with an arrow) by agarose gel electrophoresis. (D) and (E) CRTC1-induced augmentation of cccDNA formation in HepG2 and HepG2.2.15
cells was ablated by A-CREB. Nuclear cccDNA levels were measured as in (B).
erated additional reporter constructs in which the CRE el-
ements in the preS2 promoter were disrupted. Similar con-
structs were previously described (10). Indeed, progressive
removal of CRE elements effectively blunted CRTC1 acti-
vation of the preS2 promoter (Figure 5A, groups 5 and 6
compared to 4). Next, we asked whether functional CREB
is critical in supporting CRTC1 activity by overexpress-
ing A-CREB, a dominant inactive form of CREB (34).
CRTC1 activation of the preS2 promoter was erased by A-
CREB (Figure 5B, groups 3 and 4 compared to 2). Recip-
rocally, CREB activation of the preS2 promoter was pro-
gressively suppressed when we increased M1-CRTC1 ex-
pression in HepG2 cells (Figure 5C, groups 3 and 4 com-
pared to 2). In line with this, the recruitment of CRTC1
to preS2-CRE was abrogated when A-CREB was overex-
pressed in pHBV1.3D-transfected HepG2 cells (Figure 5D,
group 4 compared to 3). Reciprocal immunoprecipitation
and immunoblotting experiments confirmed the formation
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Figure 4. Suppression of CRTC1 inhibited HBV replication. (A) Expression of CRTC1 dominant inactive form (M1-CRTC1) suppressed preS2 promoter
activity. HepG2 cells were transfected with preS2-Luc (100 ng) and increasing amount of pGal-M1-CRTC1 (25, 50 and 100 ng). The difference between
groups 1 and 2 is statistically significant by Student’s t test (P = 0.0077, highlighted with **). (B) Expression of M1-CRTC decreased cccDNA levels.
Nuclear DNA was isolated and treated with plasmid-safe DNase I (Epicentre). Treated fraction was analyzed for cccDNA by quantitative PCR at the
indicated time points. Relative cccDNA level was derived by normalizing to the amount of GAPDH mRNA amplified from untreated fraction. Data
points in the plot are means from three independent experiments and error bars indicate SD. (C) Perturbation of CRTC1 with M1-CRTC1 mitigated
pgRNA expression. HepG2 cells were co-transfected with pGal-M1-CRTC1 and pHBV1.3D. Cells were harvested 48 h post-transfection for quantitative
RT-PCR analysis of pgRNA. The difference between bars 2 and 3 is statistically significant by Student’s t test (P = 0.00045, highlighted with ***); N.D.:
not detected. (D) Depletion of endogenous CRTC1 in HepG2 cells by siRNAs. Two independent CRTC1-targeting siRNAs (siCRTC1-a and siCRTC1-b)
were used to deplete endogenous CRTC1 at a concentration of 100 nM. siNC was used as a negative control. Endogenous CRTC1 in siRNA-transfected
HepG2 cells was analyzed by western blotting at 72 h post-transfection using rabbit anti-CRTC1. Concurrently, total RNA was extracted and cDNA was
synthesized. Quantitative RT-PCR was performed to analyze the relative levels of CRTC1 and CRTC2 transcripts. The difference between bars 1 and
5 is statistically significant by Student’s t test (P = 0.0018, highlighted with **). The difference between bars 2 and 6 is statistically not significant (n.s.)
by Student’s t test (P = 0.74). (E) CREB recruitment to pre-S2 promoter was diminished in CRTC1-compromised HepG2 cells. After 24 h of CRTC1
knockdown, pHBV1.3D was transfected into HepG2 cells for another 48 h. ChIP was performed as in Figure 2D. The differences between groups 2 and
3 (P = 0.00023, highlighted with ***) as well as between groups 2 and 4 (P = 0.013, highlighted with *) are statistically significant; AU: arbitrary unit.
(F) Knockdown of CRTC1 repressed pgRNA expression. The differences between groups 2 and 3 (P = 0.00031, highlighted with ***) as well as between
groups 2 and 4 (P= 0.022, highlighted with *) are statistically significant by Student’s t test. (G) Knockdown of CRTC1 dampened cccDNA level. Nuclear
cccDNA was analyzed as in Figure 3B. The differences between groups 2 and 3 (P = 0.00012, highlighted with ***) as well as between groups 2 and 4 (P
= 0.0089, highlighted with **) are statistically significant by Student’s t test. (H) CRTC1 is required for production of cell-free virus. After 24 h of CRTC1
knockdown, pHBV1.3D was transfected into HepG2 cells for another 48 h. Culture medium was centrifugated to remove debris and then detected for
HBsAg using MonolisaTM ULTRA kit (BioRad). Relative HBsAg level in siNC-transfected cells was taken as 1. The differences between groups 2 and 3
(P = 0.00071, highlighted with ***) as well as between groups 2 and 4 (P = 0.0047, highlighted with **) are statistically significant by Student’s t test.
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Figure 5. CRTC1 activates preS2 promoter through CREB. (A) Deletion of CRE in the preS2 promoter abrogated CRTC1-mediated activation. HepG2
cells were transfected with preS2-Luc/preS2-CRE(I)-Luc/preS2-CRE(I/II)-Luc (100 ng) and pcDNA3.1-V5/His-CRTC1 (100 ng). The difference be-
tween groups 4 and 5 is statistically significant by Student’s t test (P= 0.0014, highlighted with **); vec: empty vector. (B) CRTC1 activation of preS2 pro-
moter was blunted by dominant inactive CREB. HepG2 cells were transfected with preS2-Luc (100 ng), a fixed amount of pcDNA3.1-V5/His-CRTC1/2/3
(100 ng) and escalating amounts of A-CREB plasmid (10 and 20 ng). The differences between groups 2 and 3 (P = 0.0010, highlighted with **) as well as
between groups 2 and 4 (P = 0.00099, highlighted with ***) are statistically significant by Student’s t test. (C) CREB-mediated preS2 promoter activation
was ablated in the presence of dominant inactive CRTC1. HepG2 cells were transfected with preS2-Luc (100 ng), a fixed amount of Tag2B-CREB (100
ng) and escalating amounts of M1-CRTC1 plasmids (25 and 50 ng). The differences between groups 2 and 3 (P = 0.0045, highlighted with **) as well as
between groups 2 and 4 (P = 0.00040, highlighted with ***) are statistically significant by Student’s t test. (D) CRTC1 recruitment to preS2 promoter was
prevented when CREB function was compromised. ChIP was performed as in Figure 2D. The difference between groups 3 and 4 is statistically significant
by Student’s t test (P = 0.00036, highlighted with ***); N.D.: not detected.
 at U
niversity of H
ong K
ong on A
ugust 14, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2014, Vol. 42, No. 20 12463
ofCREB–CRTC1 complex inHepG2 andHepG2.2.15 cells
(Supplementary Figure S2A and B). Hence, CRTC1 re-
quires and cooperates with CREB to stimulate HBV tran-
scription.
HBx promotes CRTC1 activation of HBV transcription
Because HBx also activates CREB and is required for HBV
replication (10,19), we investigated the interplay among
HBx, CREB and CRTC1 in HBV transcription. We ob-
served that CRTC1 activation of both canonical CREs and
the preS2 promoter wasmore robust whenHBxwas also ex-
pressed (Figure 6A and B, groups 5 and 6 compared to 4).
Similar results were also obtained for CRTC2 and CRTC3
(data not shown). In addition, CRTC1 was detected in the
HBx immunoprecipitate (Figure 6C, lane 3 compared to
2), indicating their association in cultured cells. Interest-
ingly, the protein bands of both CRTC1 and HBx were
more prominent when they were co-expressed (Figure 6C,
lane 3 compared to 1 and 2), implicating a mutual stabi-
lization effect. Unexpectedly, an additional slow-migrating
HBx species was observed when CRTC1 was co-expressed
(Figure 6C, lane 3 compared to 1). Thus, CRTC1 might di-
rect HBx for additional protein modifications.
Phosphorylation of CRTC2 at S171 was thought to
trigger polyubiquitination at K628 leading to protein
degradation (35). The equivalent site in CRTC1 is S167
(24). To explore whether HBx might affect the stability
of CRTC1 through a similar mechanism, we compared
the interaction of HBx with CRTC1 and its active non-
phosphorylatable form, CRTC1-S167A.When CRTC1 and
CRTC1-S167Awere co-expressedwithHBx inHepG2 cells,
similar amounts of CRTC1 protein were found in the HBx
immunoprecipitate (Supplementary Figure S3, lane 3 com-
pared to 2). In addition, both forms of CRTC1 enhanced
the recruitment of CREB to the HBx-containing complex,
but to similar extent (Supplementary Figure S3, lanes 2 and
3 compared to 1). Thus, HBx has no binding preference to
CRTC1-S167A. On the other hand, when we overexpressed
CREB, the association ofHBx andCRTC1was not affected
(Supplementary Figure S4, lane 4 compared to 3). Consis-
tent with results in Supplementary Figure S3, both CRTC1
and CREB were found in the HBx precipitate (Supplemen-
tary Figure S4). These data were consistent with the forma-
tion of HBx–CRTC1–CREB triple complex.
Mutual stabilization of HBx and CRTC1
To further investigate mutual stabilization of HBx and
CRTC1, we expressed in HepG2 cells CRTC1 and its mu-
tant CRTC1-S167A, either individually or together with
HBx. Steady-state levels of both CRTC1 and its S167Amu-
tant were increased when HBx was expressed (Figure 7A,
lanes 5 and 6 compared to 2 and 3). On the other hand,
HBx protein expression was more pronounced and a slow-
migrating HBx species appeared when CRTC1 or CRTC1-
S167A was expressed (Figure 7A, lanes 5 and 6 compared
to 4). Hence, CRTC1 and HBx are mutually required for
optimal stability and activity.
We next examined the impact of HBx on the steady-state
levels of endogenous CRTC proteins in HepG2 cells. No-
tably, escalating dose of HBx expression correlated with in-
creased levels of CRTC1 and CRTC2, but not CRTC3 (Fig-
ure 7B, lanes 2 and 3 compared to 1). On the other hand,
when we overexpressed CRTCs individually, more promi-
nent HBx bands including the slow-migrating species were
visible (Figure 7C, lanes 2–4 compared to 1). In otherwords,
CRTC1 and its homologs were capable of stabilizing HBx.
When we depleted endogenous CRTC1 in HepG2.2.15
cells, expression of HBx protein was diminished (Figure
7D, lanes 2 and 3 compared to 1), suggesting a physio-
logical role of CRTC1 in maintaining HBx protein stabil-
ity. Such destabilization effect on HBx was unlikely due to
an effect of CRTC1 on X promoter, which was shown to
be unresponsive to CRTC1 (Figure 2B). The stabilization
of CRTC1 was also seen in pHBV1.3D-transfected HepG2
cells (Figure 7E, lane 2 compared to 1). In sharp contrast,
the steady-state level of CRTC1 remained unchanged (Fig-
ure 7E, lane 3 compared to 1 and 2) when HepG2 cells were
transfected with pHBV1.3D-X−, an X-deficient molecular
clone of HBV (25). Although an X transcript was expressed
from this clone at lower level (Figure 7E, lane 3 compared to
2), no functional HBx protein would be produced as shown
in the literature (25). Thus, the stabilization of CRTC1 in
HBV-replicating cells is HBx dependent.
To shed mechanistic light on the mutual stabilization
of HBx and CRTC1, we employed proteosome inhibitor
MG132 and a lysine-free (K0)mutant of ubiquitin (26). The
K0 mutant of ubiquitin prevents polyubiquitination and
subsequent proteasome-mediated degradation, but allows
mono- and multi-ubiquitination, which might be linked to
lysosome-dependent degradation (36,37). If mutual stabi-
lization of HBx and CRTC1 is mediated solely through
polyubiquitination and proteosome, their levels should
be unchanged or increased in the presence of MG132
or ubiquitin-K0. Interestingly, the steady-state levels of
CRTC1 andHBx decreased only slightly when the cells were
treated with MG132 (Figure 7F, lane 4 compared to 3), im-
plicating a role for proteosome in the stabilization effect.
However, the expression of ubiquitin-K0 abrogated this sta-
bilization effect almost completely (Figure 7F, lane 5 com-
pared to 1–4). Although there was no simple interpreta-
tion to this result, one possibility is that mono- or multi-
ubiquitination of HBx and CRTC1 might promote their
proteosomal degradation. Plausibly, the stability of HBx
and CRTC1 might be governed by multiple mechanisms in-
volving ubiquitination, proteosome and lysosome.
DISCUSSION
In this study we provided the first evidence for the require-
ment of CRTC1 coactivator for HBV transcription and
replication. Our work contributes at least three new mes-
sages concerning the role of CRTC1 in HBV infection.
First, CRTC1 protein was abundantly expressed in HBV-
infected cells (Figure 1). Second, CRTC1 and its homologs
(CRTC2 and CRTC3) are recruited to the preS2 promoter
and cccDNA to mediate transcriptional activation in coop-
erationwith CREB (Figures 2–5). Finally, HBx functions to
stabilize and promote CRTC1 activation of HBV transcrip-
tion (Figures 6 and 7). Our findings reveal a new cellular
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Figure 6. Cooperation between CRTC1 and HBx in the activation of preS2 promoter. (A) and (B) HepG2 cells were transfected with pCRE-Luc or
preS2-Luc (100 ng), a fixed amount of pcDNA3.1-V5/His-CRTC1 (100 ng) and escalating amounts (50 and 100 ng) of pCAGEN-Flag-HA-HBx. Fold
activation is calculated from preS2-Luc activity normalized to that of pSV-RLuc. The differences between groups 4 and 5 (P = 0.024 for A and P =
0.020 for B, highlighted with *) as well as between groups 4 and 6 (P = 0.0051 for A and P = 0.000051 for B, highlighted with ** and ***, respectively)
are statistically significant by Student’s t test. (C) Association of CRTC1 with HBx. HepG2 cells were transfected with pcDNA3.1-V5/His-CRTC1 and
pCAGEN-Flag-HA-HBx. HBx was precipitated with anti-Flag. The precipitates and the input lysates were probed with mouse anti-Flag, mouse anti-V5
and rabbit anti-CREB; -tub: -tubulin.
accessory factor and a new layer of regulation in HBV gene
expression.
CRTC1 is particularly stabilized in HBV-infected cells
(Figure 1). This stabilization effect is specific to CRTC1
(Figure 1). Although CRTC2 and CRTC3 expression was
not found to be elevated in HBV-infected cells, they were
also capable of occupying the preS2 promoter, stabilizing
HBx and activating HBV transcription (Figures 2, 3 and 7).
In other words, they are fully competent to regulate HBV
gene expression. Because they might be induced and acti-
vated in response to metabolic stress and hormones (33),
further studies are required to elucidate how they modulate
HBV transcription under the influence of their metabolic
and hormonal activators.
Promoter context is a decisive factor in the requirement
of CRTC coactivators for transcriptional activation of cel-
lular CRE-dependent genes (32,33). Our demonstration of
CRTC activation of the preS2 but not the X promoter of
HBV (Figure 2) supports the notion that the coactivator
function of CRTCs in HBV transcription is also promoter
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Figure 7. Mutual stabilization of CRTC1 and HBx. (A) HepG2 cells were transfected with pcDNA3.1-V5/His-CRTC1 WT/S167A and pCAGEN-Flag-
HA-HBx as indicated. Cell lysates were analyzed by western blotting. (B) Stabilization of endogenous CRTC1/2 byHBx.HepG2 cells were transfected with
escalating amounts (0.5 and 1 g) of pCAGEN-Flag-HA-HBx. Expression of endogenous CRTC1/2/3 was analyzed by western blotting. (C) Stabilization
of HBx by CRTC1/2/3. HepG2 cells were transfected with pCAGEN-Flag-HA-HBx and pcDNA3.1-V5/His-CRTC1/2/3. (D) Compromising CRTC1
led to diminution of HBx protein. HepG2.2.15 cells were transfected with siNC or siCRTC1 for 48 h. (E) HBx-dependent stabilization of CRTC1 in HBV-
replicating cells. HepG2 cells were transfected with pHBV1.3D or its HBx-deficient mutant pHBV1.3D-X−, in which the expression of HBx protein was
abrogated. CRTC1 expression was analyzed by western blotting. RT-PCR was also performed to verify the expression of X transcript and pgRNA. (F)
Stabilization of CRTC1 and HBx requires ubiquitination and proteosome. HepG2 cells were transfected with the indicated combinations of pcDNA3.1-
V5/His-CRTC1, pCAGEN-Flag-HA-HBx and an expression vector for K0 mutant of ubiquitin. Cells in group 4 were treated with 20 M of MG132 for
4 h.
context dependent. Although the exact promoter context
that governs CRTC requirement is not currently under-
stood, a comparison of the preS2 and X promoters sheds
some light on this issue. Noteworthily, there are two con-
secutive CREs in the preS2 promoter, both of which are re-
quired for optimal activation by CRTC1 (Figure 5). In con-
trast, only one single CRE has been found in the X pro-
moter (11). Further experiments should therefore be per-
formed to determine whether this difference in the number
of CREs might be decisive in promoter responsiveness to
CRTCs.
Our results supported the model in which CRTCs coop-
erate with CREB to activate the preS2 promoter (Figure
5). We also showed the recruitment of CRTCs to cccDNA
and preS2-CRE in pHBV1.3D-transfected cells (Figure 2).
These findings support amore direct involvement of CRTCs
in HBV transcription from cccDNA. However, an indi-
rect stimulatory role of CRTC2 on the core promoter me-
diated through PGC1 has also been suggested (13). We
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also observed a modest activation of the preS1 and core
promoters by all three CRTCs (Supplementary Figure S1).
However, since no CRE has been found in these promot-
ers, their general and mild activation by CRTCs is likely
mediated indirectly through a CREB-regulated gene such
as PGC1. Thus, the influence of CRTCs on HBV tran-
scription might be exerted through both direct activation
as demonstrated in our study and an indirect effect as sug-
gested for CRTC2 (13). Particularly, the stimulatory effect
of CRTCs on pgRNA expression (Figure 3) could be medi-
ated through the core promoter.
The activation of the preS2 promoter by CRTC1 was me-
diated through CREB and CRE (Figures 2 and 5). The
structural interface of CRTC2 for recognition and coac-
tivation of CREB has been determined (38). In addition,
the regulation of CRTC2 nucleocytoplasmic shuttling by
upstream kinases has also been characterized (39). Plau-
sibly, CRTC1 would use a similar interface to recognize
CREB and CRTC1 activity would be regulated by the same
protein kinases in the context of HBV transcription. It is
noteworthy that small molecule activators and inhibitors of
LKB1 and its downstream protein kinases, including met-
formin and salicylate, have been well documented (16,40).
We have recently shown that LKB1 and its downstream ki-
nases potently suppress transcriptional activity of CRTC1
and CREB in the context of human T-cell leukemia type 1
virus infection. In addition, the activation of these kinases
using small molecule agonists such as metformin exhibits
strong antiretroviral effects (27). By the same token, our
characterization of the role of CRTCs in HBV life cycle will
pave the way for further investigations on pharmacological
inhibition of HBV transcription.
HBx activates HBV and cellular gene expression through
multiple mechanisms. Particularly, HBx stimulates CREB-
dependent transcription by cooperating with p300/CBP
coactivators (20), promoting CREB dimerization (21) and
inhibiting negative regulators (41). Our documentation
of the interaction and mutual stabilization of HBx and
CRTC1/2 (Figures 6 and 7) provides a new mechanism by
which HBx regulates HBV transcription. Since CRTCs are
essential coactivators of CREB-dependent transcription of
both HBV and cellular promoters, HBx might also modu-
late cellular CRE-dependent promoters through its interac-
tion and stabilization of CRTC1/2.
The mutual stabilization of HBX and CRTC1/2 in HBV-
infected cells (Figure 7) is attributed at least in part to their
interaction (Figure 6). This stabilization unlikely occurs at
the mRNA level since CRTCmRNAs remained unchanged
in pHBV1.3D-transfected cells (Figure 1C) in which HBx
was abundantly expressed (Figure 1B). In addition, the sta-
bilization of HBx was seen not only when it was expressed
from a plasmid in transfected HepG2 cells but also when
it was expressed in HepG2.2.15 cells from its own pro-
moter in the HBV genome (Figure 7), which is not respon-
sive to CRTCs (Figure 2). The mechanism by which HBx
and CRTC1/2 proteins mutually stabilize each other war-
rants further study. First, the functional domains in HBx
and CRTC1/2 that mediate their interaction and stabiliza-
tion should be determined. CRTC3 is more divergent from
CRTC1/2 and smaller in size; comparative analysis might
reveal why CRTC3 was not stabilized by HBx (Figure 7).
Although CRTC2 level was elevated in HepG2 cells ex-
pressing HBx (Figure 7), it was unchanged in HepG2.2.15
or pHBV1.3D-transfected HepG2 cells (Figure 1). Further
investigations are required to resolve this discrepancy and
to clarify whether and how other viral proteins might af-
fect CRTC2 protein expression. Second, the slow-migrating
form of HBx detected in the presence of CRTC1/2/3 (Fig-
ure 7) should be further characterized. Particularly, whether
it represented mono- or multi-ubiquitinated HBx should be
clarified. Finally, exactly how stability of HBx and CRTCs
in HBV-infected cells would be regulated through ubiquiti-
nation and proteolysis should be clarified. HBx has previ-
ously been shown to stabilize AIB1 oncoprotein by prevent-
ing its ubiquitination and proteosomal degradation (42). In
view of the minimal to mild effect of MG132 on the mu-
tual stabilization of HBx and CRTC1 (Figure 7), a role for
polyubiquitination and proteosome was suggested. How-
ever, the abrogation of the mutual stabilization effect by
ubiquitin-K0 pointed to another direction. This discrep-
ancy should be resolved in future work. The possibility that
HBx and CRTC1 might be mono- or multi-ubiquitinated
and then degraded by the lysosome should be experimen-
tally validated. Alternatively, K63-linked or other types of
polyubiquitination of CRTC1 suppressed by ubiquitin-K0
might be required for its stabilization. Our data cannot ex-
clude thatmultiplemechanismsmight operate in the control
of HBx and CRTC stability. Further investigations should
be performed to determine the involvement of proteosome,
lysosome and different types of ubiquitination in the de-
struction of HBx and CRTCs in HBV-infected cells.
Results from our gain-of-function and loss-of-function
assays consistently supported the requirement of CRTC1
for HBV replication, as indicated in the production of
pgRNA, cccDNA and secreted HBsAg (Figures 3 and 4).
This is generally consistent with the notion that CRTC1-
regulated HBV transcription is influential in viral repli-
cation. The decline of cccDNA level upon CRTC1 sup-
pression (Figure 4) is noteworthy. It raises one interest-
ing possibility that compromising CRTC1 might destabi-
lize cccDNA. Histone hypoacetylation is known to regu-
late cccDNA transcription (43). APOBEC3-mediated cyti-
dine deamination has recently been shown to trigger specific
degradation of cccDNA (8). Whether and how CRTC1 re-
cruitment to cccDNA and its post-translational modifica-
tions might affect cccDNA stability and function merit fur-
ther investigations.
CREB and CRTCs have oncogenic potential in various
types of cancer (44,45). Our present study reveals a novel
function of CRTC1 in HBV transcription and replication.
The stabilization and activation of CRTC1 were observed
both in HepG2 cells freshly transfected with pHBV1.3D
and in HepG2.2.15 cells constitutively harboring HBV
genome (Figures 2 and 6). CRTC1 might plausibly play a
role in both acute and chronic phase of HBV infection.
However, it will still be of importance to characterize in
more detail the stabilization of CRTC1 in different phases
of HBV infection and HCC development. Particularly, fur-
ther investigations are required to clarify whether CRTC1
might be critical in HBV reactivation as well as initiation
and progression of HCC.
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